Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: Data from the SENTRY antifungal surveillance program (2010-2012)

Journal of Antibiotics

Volumn 68, Issue 9, 2015, Pages 556-561

  Pfaller, Michael A ^a   Messer, Shawn A ^a   Jones, Ronald N ^a   Castanheira, Mariana ^a  

^a JMI LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASIA; ASPERGILLUS FUMIGATUS; BIOGEOGRAPHIC REGION; CANDIDA; CRYPTOCOCCUS NEOFORMANS; DRUG SURVEILLANCE PROGRAM; FUNGUS ISOLATION; HONG KONG; INDIA; KOREA; MINIMUM INHIBITORY CONCENTRATION; MOULD; MULTIDRUG RESISTANCE; NEW ZEALAND; NONHUMAN; PRIORITY JOURNAL; SINGAPORE; SOUTH AFRICA; SYSTEMIC MYCOSIS; TAIWAN; THAILAND; WESTERN PACIFIC; YEAST; ANTIFUNGAL RESISTANCE; DRUG EFFECTS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; PACIFIC ISLANDS;

ANTIFUNGAL AGENTS; ASIA; ASPERGILLUS FUMIGATUS; CANDIDA; CRYPTOCOCCUS NEOFORMANS; DRUG RESISTANCE, FUNGAL; HUMANS; MICROBIAL SENSITIVITY TESTS; PACIFIC ISLANDS;

EID: 84942763975     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2015.29     Document Type: Article

References (43)

1. Arendrup, M. C. Epidemiology of invasive candidiasis. Curr. Opin. Crit. Care. 16, 445-452 (2010).
2. Azie,N.et al. The PATH (Prospective Antifungal Therapy) Alliance registry and invasive fungal infections: update 2012. Diagn. Microbiol. Infect. Dis. 73, 293-300 (2012).
3. Cleveland, A. A. et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin. Infect. Dis. 55, 1352-1361 (2012).
4. Howard, S. J. & Arendrup, M. C. Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection. Med. Mycol. 49(Suppl 1), S90-S95 (2011).
5. Peman,J.et al. Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey. J. Antimicrob. Chemother. 67, 1181-1187 (2012).
6. Pfaller, M. A. & Diekema, D. J. Epidemiology of invasive candidiasis: A persistent public health problem. Clin. Microbiol. Rev. 20, 133-163 (2007).
7. Pfaller, M. A., Messer, S. A., Woosley, L. N., Jones, R. N. & Castanheira, M. Echinocandin and triazole antifungal susceptibility profiles of opportunistic yeast and mould clinical isolates (2010-2011); application of new CLSI clinical breakpoints and epidemiological cutoff values to characterize geographic and temporal trends of antifungal resistance. J. Clin. Microbiol. 51, 2571-2581 (2013).
8. Slavin, M. A. & Chakrabarti, A. Opportunistic fungal infections in the Asia-Pacific region. Med. Mycol. 50, 18-25 (2012).
9. Sun, P. L. et al. Laboratory-based surveillance of human fungal pathogens in Asia. Mycoses 55, 49 (2012).
10. Chen, S. et al. Active surveillance for candidemia, Australia. Emerg. Infect. Dis. 12, 1508-1516 (2006).
11. Chen, S. C. et al. Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management. Clin. Microbiol. Infect. 15, 662-669 (2009).
12. Chakrabarti, A., Chander, J., Kasturi, P. & Panigrahi, D. Candidaemia: A 10-year study in an Indian teaching hospital. Mycoses 35, 47-51 (1992).
13. Chakrabarti, A. et al. Epidemiological study of a large cluster of fungaemia cases due to Kodamaea ohmeri in an Indian tertiary care centre. Clin. Microbiol. Infect. 20, O83-O89 (2014).
14. Takakura, S. et al. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J. Antimicrob. Chemother. 53, 283-289 (2004).
15. Choi, H. W. et al. In vitro susceptibilities to caspofungin and micafungin of clinical isolates of Candida species. Korean J. Lab. Med. 26, 275-281 (2006).
16. Jang, M. J. et al. In vitro fluconazole and voriconazole susceptibilities of Candida bloodstream isolates in Korea: use of the CLSI and EUCAST epidemiological cutoff values. Ann. Lab. Med. 33, 167-173 (2013).
17. Jung, S. I. et al. Multicenter surveillance of species distribution and antifungal susceptibilities of Candida bloodstream isolates in South Korea. Med. Mycol. 48, 669-674 (2010).
18. Lee, J. S. et al. Species distribution and susceptibility to azole antifungals of Candida bloodstream isolates from eight university hospitals in Korea. Yonsei Med. J. 48, 779-786 (2007).
19. Santhanam, J., Nazmiah, N. & Aziz, M. N. Species distribution and antifungal susceptibility patterns of Candida species: Is low susceptibility to itraconazole a trend in Malaysia? Med. J. Malaysia 68, 343-347 (2013).
20. Tan, T. Y., Tan, A. L., Tee, N. W. & Ng, L. S. A retrospective analysis of antifungal susceptibilities of Candida bloodstream isolates from Singapore hospitals. Ann. Acad. Med. Singapore 37, 835-840 (2008).
21. Chen, P. L. et al. Species distribution and antifungal susceptibility of blood Candida isolates at a tertiary hospital in southern Taiwan, 1999-2006. Mycoses 54, e17-e23 (2011).
22. Hii, I. M. et al. Changing epidemiology of candidemia in a medical center in middle Taiwan. J. Microbiol. Immunol. Infect. (e-pub ahead of print 7 October 2013; doi:10.1016/j.jmii.2013.08.017).
23. Hsueh, P. R., Teng, L. J., Yang, P. C., Ho, S. W. & Luh, K. T. Emergence of nosocomial candidemia at a teaching hospital in Taiwan from 1981 to 2000: increased susceptibility of Candida species to fluconazole. Microb. Drug Resist. 8, 311-319 (2002).
24. Lai, C. C. et al. Association between incidence of candidaemia and consumption of antifungal agents at a medical centre in Taiwan. Int. J. Antimicrob. Agents 40, 349-353 (2012).
25. Hsueh, P. R. et al. Consensus statement on the management of invasive candidiasis in intensive care units in the Asia-Pacific Region. Int. J. Antimicrob. Agents 34, 205-209 (2009).
26. Ruan, S. Y., Lee, L. N., Jerng, J. S., Yu, C. J. & Hsueh, P. R. Candida glabrata fungaemia in intensive care units. Clin. Microbiol. Infect. 14, 136-140 (2008).
27. Yang, Y. L., Ho, Y. A., Cheng, H. H., Ho, M. & Lo, H. J. Susceptibilities of Candida species to amphotericin B and fluconazole: The emergence of fluconazole resistance in Candida tropicalis. Infect. Control Hosp. Epidemiol. 25, 60-64 (2004).
28. Pfaller, M. A., Castanheira, M., Messer, S. A., Moet, G. J. & Jones, R. N. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: Application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn. Microbiol. Infect. Dis. 69, 45-50 (2011).
29. Pfaller, M. A., Woosley, L. N., Messer, S. A., Jones, R. N. & Castanheira, M. Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance program. Mycopathologia 174, 259-271 (2012).
30. Pfaller, M. A., Castanheira, M., Messer, S. A., Jones, R. N. In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012. Mycoses. 58, 209-214 (2015).
31. Pfaller, M. A. & Diekema, D. J. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J. Clin. Microbiol. 50, 2846-2856 (2012).
32. Espinel-Ingroff, A. et al. Wild-Type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J. Clin. Microbiol. 48, 3251-3257 (2010).
33. Espinel-Ingroff, A. et al. Cryptococcus neoformans-Cryptococcus gattii species complex: An international study of wild-Type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob. Agents Chemother. 56, 5898-5906 (2012).
34. Howell, S. A. & Hazen, K. C. in: Candida, Cryptococcus, and other yeasts of medical importance (eds Versalovic J., Carroll K. C., Funke G., Jorgensen J. H., Landry M. L., Warnock D. W.) Manual of Clinical Microbiology 10th edn 1793-1821 (ASM Press, Washington, DC, USA, 2011).
35. Larone, D. H. Medically important fungi: A guide to identification 4th edn (ASM Press, Washington, DC, USA, 2002).
36. CLSI. M27-A3. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts 3rd edn (Clinical and Laboratory Standards Institute, Wayne, PA, USA, 2008).
37. CLSI. M27-S4. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts 4th Informational Supplement (Clinical and Laboratory Standards Institute, Wayne, PA, USA, 2012).
38. CLSI. M38-A2. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi 2nd edn (Clinical and Laboratory Standards Institute, Wayne, PA, USA, 2008).
39. Howard, S. J. et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 15, 1068-1076 (2009).
40. Rodriguez-Tudela, J. L. et al. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob. Agents Chemother. 52, 2468-2472 (2008).
41. Castanheira, M. et al. Low prevalence of fks1 hotspot 1 mutations in a worldwide collection of Candida spp. Antimicrob. Agents Chemother. 54, 2655-2659 (2010).
42. Castanheira, M. et al. Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates. Antimicrob. Agents Chemother. 58, 577-580 (2014).
43. Espinel-Ingroff, A. et al. Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole. Antimicrob. Agents Chemother. 58, 2006-2012 (2014).